PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted - Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 **5**:15

Section/topic	"_	Checklist item	Information reported		Line				
	#		Yes	No	number(s)				
ADMINISTRATIVE INFORMATION									
Title									
Identification	1a	Identify the report as a protocol of a systematic review			Page 1, Lines 9-14				
Update	1b	If the protocol is for an update of a previous systematic review, identify as such							
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract							
Authors	Authors								
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			Page 1, Lines 16-21; Page 2, Lines 6-15; Page 12, Lines 26-37				
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			Page 11, Lines 59-63; Page 12, Lines 5-7				
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments							
Support									
Sources	5a	Indicate sources of financial or other support for the review							



Section/topic	#	Checklist item	Information reported		Line
			Yes	No	number(s)
Sponsor	5b	Provide name for the review funder and/or sponsor			Page 12; Lines 19-22
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol			
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known			Page 4, Lines 35-47
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)			
METHODS		T. C.			1
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review			Page 6, Lines 58-63; Page 7, Lines 5-47
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage			Page 7, Lines 19-21, 49-63
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			Page 8, Lines 5-17
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review			Page 8, Lines 17-24
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)			Page 8, Lines 25-63; Page 9, Lines 5-63
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators			Page 10, Lines 39-54
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications			Page 10, Lines 5-37
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale			Page 11, Lines 19-31



Section/topic	#	Checklist item	Information reported		Line		
			Yes	No	number(s)		
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis					
DATA							
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized					
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)					
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)		\boxtimes			
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned			Page 10, Lines 56- 63;Page 11, Lines 5-19		
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)		\boxtimes			
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)		\boxtimes			

